CULLINAN THERAPEUTICS, INC. Revenue Breakdown
No Revenue Breakdown for CGEM on this site yet.
- 2022-12-31: Total revenue $0.00.
- 2021-12-31: Others Not split by product in the filing$18.94M100.00%; Total revenue $18.94M.
- 2020-12-31: Total revenue $0.00.
Source checked: the stored Revenue Breakdown page for CGEM.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2022-12-31 | $0.00 | |
| 2021-12-31 | Not split by product in the filing $18.94M 100.00% | $18.94M |
| 2020-12-31 | $0.00 |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2022-12-31 | Not split by product $0.00 | $0.00 |
| 2022-09-30 | Not split by product $0.00 | $0.00 |
| 2022-06-30 | Not split by product $0.00 | $0.00 |
| 2022-03-31 | Not split by product $0.00 | $0.00 |
| 2021-12-31 | Not split by product $0.00 | $0.00 |
| 2021-09-30 | Not split by product $0.00 | $0.00 |
| 2021-06-30 | Not split by product $0.00 | $0.00 |
| 2021-03-31 | Not split by product $18.94M 100.00% | $18.94M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |